MedTrace Logo

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects

NCT05737485 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-04-29

No results posted yet for this study

Summary

This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.

Conditions

  • Primary Ciliary Dyskinesia

Interventions

DRUG

RCT1100

RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer

Sponsors & Collaborators

  • ReCode Therapeutics

    lead INDUSTRY

Principal Investigators

  • John Matthews, MBBS, MCRP, PhD · ReCode Therapeutics, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-18
Primary Completion
2024-07-25
Completion
2025-01-13
FDA Drug
Yes

Countries

  • United States
  • Australia
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05737485 on ClinicalTrials.gov